Placental vascular dysfunction has been linked to insufficiency/deficiency of maternal vitamin D levels during pregnancy. In contrast, sufficient maternal vitamin D levels have shown beneficial effects on pregnancy outcomes. To study the role of vitamin D in pregnancy, we tested our hypothesis that vitamin D exerts beneficial effects on placental vasculature. We examined expression of CYP2R1, CYP27B1, vitamin D receptor (VDR), and CYP24A1 in placental vascular smooth muscle cells (VSMCs) in response to 1,25(OH) 2 D 3 . We found that VDR expression was inducible, CYP27B1 expression was dose-dependently downregulated, and CYP24A1 expression was dose-dependently upregulated in cells treated with 1,25(OH) 2 D 3 . These data suggest a feedback autoregulatory system of vitamin D existing in placental VSMCs. Using a VSMC/collagen-gel contraction assay, we evaluated the effect of 1,25(OH) 2 D 3 on placental VSMC contractility. We found that, similar to losartan, 1,25(OH) 2 D 3 could diminish angiotensin II-induced cell contractility. The mechanism of 1,25(OH) 2 D 3 -mediated VSMC relaxation was further explored by examination of Rho-associated protein kinase 1 (ROCK1)/phosphorylation of myosin phosphatase target subunit 1 (MYPT1) pathway molecules. Our results showed that p-MYPT1 Thr853 and p-MYPT1 Thr696 were undetectable. However, p-MYPT1 Ser507 , but not p-MYPT1 Ser668 , was significantly upregulated in cells treated with losartan plus angiotensin II. Similar effects were also seen in cells treated with 1,25(OH) 2 D 3 plus angiotensin II or 1,25(OH) 2 D 3 plus losartan plus angiotensin II. Because MYPT1 serine phosphorylation could activate myosin light chain phosphatase (MLCP), and MLCP activation is an important regulatory machinery of smooth muscle cell relaxation, up-regulation of MYPT1 Ser507 phosphorylation could be a mechanism of vitamin D and/or losartan mediated placental VSMC relaxation.
INTRODUCTION
In recent years, vitamin D has increasingly been recognized as having significant effects on organ development and cardiovascular health. Epidemiologic studies revealed that there is an inverse correlation between blood levels of vitamin D and many chronic or acute cardiovascular-related diseases, including hypertension, coronary artery and peripheral vascular diseases, myocardial infarction, heart failure, stroke, hyperlipidemia, diabetes, and others [1] [2] [3] [4] , suggesting that vitamin D deficiency is an independent risk factor for cardiovascular events [2] . Vitamin D insufficiency/deficiency during pregnancy has also been found to be associated with increased risks of maternal and fetal morbidities such as pre-eclampsia, intrauterine growth restriction, gestational diabetes, and preterm birth [5] [6] [7] [8] . Conversely, increasing vitamin D intake during pregnancy appears to afford protection to both the mother and the developing fetus, with lower risk of pregnancy complications [9] [10] [11] .
Placental vascular development and proper placental blood perfusion are fundamental for a successful pregnancy. It is well known that placental vascular dysfunction negatively affects fetal growth [12] , and importantly, placental vascular dysfunction was found to be linked to maternal vitamin D insufficiency/deficiency during pregnancy [13] . We previously reported that vitamin D metabolic components, including vitamin D binding protein (VDBP), vitamin D 25-hydroxylase (CYP2R1), 25-hydroxyvitamin D 3 1-alpha-hydroxylase (CYP27B1), vitamin D receptor (VDR), and 1,25-dihydroxyvitamin D 3 24-hydroxylase (CYP24A1), were all present in placental trophoblasts [14] . CYP2R1 and CYP27B1 are 2 vitamin D-converting enzymes. The former enzyme converts cholecalciferol into 25-hydroxyvitamin D and the latter converts 25-hydroxyvitamin D into 1,25-hydroxyvitamin D (1, 25 [OH] 2 D 3 ). The function of CYP24A1 is to degrade 1,25(OH) 2 D 3 . Altered trophoblast expression of VDBP, CYP2R1, and VDR was found to be associated with increased oxidative stress in pre-eclampsia [14] , a pregnancy disorder relating to placental vascular dysfunction. Our recent study also revealed that vitamin D could promote angiogenic activity of placental vessel endothelial cells [15] . However, little information is available about effects of vitamin D on vasoactivity of placental vasculature. To explore the potential role of vitamin D in placental vascular function, in the present study we isolated vascular smooth muscle cells (VSMCs) from normal-term placentas and specifically examined vitamin D metabolic component expression, including CYP2R1, CYP27B1, VDR, and CYP24A1 in placental VSMCs. Using a collagen-gel contraction assay, we determined effects of bioactive vitamin D 1,25(OH) 2 D 3 on contractility of placental VSMC stimulated with angiotensin II. Our results showed that 1,25(OH) 2 D 3 not only reduced placental VSMC contractility induced by angiotensin II but also potentiated losartan to promote placental VSMC relaxation. The mechanism of 1,25(OH) 2 D 3 -mediated placental VSMC relaxation was further assessed by determination of Rho-associated protein kinase 1 (ROCK1)/myosin phosphatase regulatory target unit 1 (MYPT1) pathway molecule expression. Strikingly, we found that 1,25(OH) 2 D 3 in the presence of angiotensin II downregulated ROCK1 expression and up-regulated MYPT1 phosphorylation at serine 507 (p-MYPT1 Ser507 ) expression, similar to the effect found with losartan when it is combined with angiotensin II. Because MYPT1 is the major subunit involved in myosin light chain phosphatase (MLCP) activation, which is essential for vessel vasodilation [16] , phosphorylation of MYPT1 Ser507 induced by 1,25(OH) 2 D 3 could be a cellular and molecular mechanism of 1,25(OH) 2 D 3 -mediated relaxation of placental VSMCs.
MATERIALS AND METHODS

Chemicals and Reagents
Dulbecco modified Eagles medium (DMEM), 1,25(OH) 2 D 3 , losartan, and angiotensin II were purchased from Sigma Chemicals (St. Louis, MO). Antibodies for CYP27B1 (product H-90; code sc-67261), VDR (product D-6; code sc-13133), CYP24A1 (product H-87; code sc-66851), AT-1 (product N-10; code sc1173), AT-2 (product H-143; code sc-9040), CD31 (product M-20; code sc-1506), vimentin (product V-9; code sc-6260), and ROCK1 (product G-6; code sc-17794) were purchased from Santa Cruz Biotechnology (Dallas, TX). Antibody for CYP2R1 (product S1968) was from Epitomics (Burlingame, CA), and anti-human smooth muscle actin (product M0851) was from Dako Denmark (Carpinteria, CA). Antibodies for RhoA (products 67B9 and 2117P), MYPT1 (products D6C1 and 8574S), p-MYPT1 Thr853 (at threonine 853 [product 4563P]), p-MYPT1 Thr696 (product 5163P), p-MYPT1 Ser668 (product 5143P), and p-MYPT1 Ser507 (product 3040P) were obtained from Cell Signaling Technology (Danvers, MA). b-actin antibody was from Sigma Chemicals. All other chemicals and reagents were from Sigma Chemicals unless otherwise noted.
Placental VSMC Isolation and Rat Tail Type I Collagen Extraction
Placental VSMCs were isolated from tertiary chorionic plate arteries from normal-term placentas as previously described [17] , and VSMCs at passages 3-5 were used in the present study. Placental VSMCs were cultured with DMEM supplemented with 10% fetal bovine serum and antibiotics in a humidified cell culture incubator at 378C with 5% CO 2 . Isolated placental VSMCs exhibited positive staining for human smooth muscle actin and vimentin and negative staining for CD31. Collection of placentas was approved by the Institutional Review Board for Human Research at Louisiana State University Health Science Center-Shreveport.
Rat tail type I collagen was prepared as previously described [17, 18] . Briefly, rat tail type I collagen was extracted by digestion of rat tail tendons in sterile 4 mM acetic acid for 48 h at 48C. Undigested tendon pieces were removed by filtration through 250-lm nylon filter (Spectrum Labs, Rancho Dominguez, CA). After centrifugation, collagen solution was divided into aliquots which were lyophilized by using a bench-top manifold freeze-dryer unit (Millrock Technology, Kingston, NY) and stored at À208C for future use.
Preparation of Placental VSMC/Collagen Gel
Lyophilized collagen was solubilized with cold 0.012 M hydrochloric acid under constant agitation overnight at 48C, until all collagen resolved. On the day of assay, the pH of collagen solution was quickly titrated at 7.3-7.4 by 1 N NaOH on ice. Placental VSMCs pretreated with 1,25(OH) 2 D 3 (100 nM for 24 h) were harvested by trypsin-EDTA, suspended in serum-free DMEM, and then quickly added to collagen solution on ice. The final concentration of placental VSMC/ collagen mixture was 10 5 cells/2.5 mg of collagen/ml. An aliquot of 500 ll placental VSMC/collagen mixture was then loaded per well into 24-well plates. The placental VSMC/collagen mixture was allowed to polymerize at 378C for 1 h, and then 1.0 ml of serum-free DMEM supplemented with different agents (see below) was added to each well. Gels were detached from the edge of the wells with an L-shaped blunted glass pipette tip and allowed to float freely [17, 18] .
Placental VSMC/Collagen Gel Contraction Assay
To study effects of vitamin D on VSMC contractile activity, placental VSMC/collagen gel contraction assays were performed. Because reninangiotensin system is present in the placenta, angiotensin II (10 À7 M) was used to stimulate VSMC contraction, and losartan (10 À4 M) was used to block angiotensin II receptor activity. 1,25(OH) 2 D 3 (100 nM) was used as a bioactive vitamin D. VSMC/collagen gel was incubated with 1 ml serum-free DMEM with different treatments in 6 groups, as follows: 1) untreated control, 2) angiotensin II alone, 3) losartan plus angiotensin II, 4) 1,25(OH) 2 D 3 alone, 5) 1,25(OH) 2 D 3 plus angiotensin II, and 6) 1,25(OH) 2 D 3 plus losartan plus angiotensin II. Gels were incubated at 378C in 5% CO 2 for 7 days. Angiotensin II, losartan, or 1,25(OH) 2 D 3 was added to culture wells every 24 h. Plates were scanned every 24 h using an Epson flatbed scanner (Long Beach, CA) over 7 days to monitor changes of gel area. For data analysis, the area of the gel in each well was measured by ImageJ imaging analysis software (National Institutes of Health, Bethesda, MD). Gel contractility (X) was defined as the change in gel surface area on Day 7 (Y) as a fraction of its area measured on Day 0 (Z) and then normalized to the internal control in each assay ( [18] . Gel contraction of control wells on Day 7 was set as 100% contraction. Final data were expressed as mean 6 SEM from 5 independent experiments with triplicate wells in each group.
Protein Expression
To study vitamin D metabolic system in placental VSMCs, confluent cells were treated with 1,25(OH) 2 D 3 at concentrations of 0, 5, 10, 20, 50, or 100 nM for 24 h. Cells were then lysed with lysis buffer containing 50 mmol/L Tris, 0.5% NP40, 0.5% Triton X-100 with protease, and phosphatase inhibitors, and total cellular protein was collected. Protein expression levels for CYP2R1, CYP27B1, VDR, and CYP24A1 were determined by Western blotting. To explore the mechanism of vitamin D-induced relaxation of placental VSMCs, RhoA and ROCK1 expression and phosphorylation of MYPT1 signaling pathway molecule expression for MYPT1, p-MYPT1
, and p-MYPT1 Ser507 were determined by Western blot analysis. In addition, protein expression for VDR, AT-1, and AT-2 were also determined. For Western blotting, 10 lg of cellular protein per sample was subject to electrophoresis (Bio-Rad Laboratories, Hercules, CA) and then transferred to nitrocellulose membranes. After being blocked, membranes were probed with a specific antibody, followed by a matched secondary antibody. The bound antibody was visualized with an enhanced chemiluminescent detection kit (Amersham Corp., Arlington Heights, IL) and exposed by sandwiching with X-ray film. Membranes were then stripped, blocked, and reprobed with different antibodies. The density was scanned and analyzed using ImageJ analysis software. b-actin or MYPT1 expression was used to normalize the target protein expression for each sample. Data are mean 6 SEM from 3 to 5 independent experiments.
Statistical Analysis
Data are mean 6 SEM and were analyzed by using analysis of variance (ANOVA) with Student-Newman Keuls test as post hoc test or by paired Student t-test with Prism 5 software (GraphPad, Inc., La Jolla, CA). A probability level less than 0.05 was considered statistically significant. JIA ET AL.
RESULTS
Effects of 1,25(OH) 2 D 3 on Vitamin D Metabolic System in Placental VSMCs
We first examined expression of the vitamin D metabolic system including CYP2R1, CYP27B1, VDR, and CYP24A1 in placental VSMCs treated with or without 1,25(OH) 2 D 3 . Figure  1A shows representative Western blots for CYP2R1, CYP27B1, VDR, and CYP24A1 in control cells and in cells treated with different concentrations of 1,25(OH) 2 D 3 . Figure 1B shows the relative density of expression levels for proteins CYP2R1, CYP27B1, VDR, and CYP24A1 after normalization with bactin expression for each sample. Data are means from 4 to 5 independent experiments. Our results clearly showed that placental VSMCs expressed comparative amounts of CYP2R1, CYP27B1, and CYP24A1 in control cells. CYP2R1 expression was up-regulated in cells treated with 1,25(OH) 2 Because vitamin D has beneficial effects on cardiac vasculature [19] and because vitamin D metabolic components are present in placental VSMCs, we then determined whether vitamin D exerted beneficial effects on placental VSMCs. More specifically, we determined the role of vitamin D in placental VSMC contractility. This was evaluated by VSMC/collagen gel contraction assay. Angiotensin II was used as the stimulator to induce cell contraction. As a comparison, the angiotensin II receptor-1 (AT-1) blocker losartan was used to inhibit angiotensin II-induced placental VSMC contractility. Figure  2A Figure 4 . Figure 4A shows 
DISCUSSION
Vitamin D Biosynthesis System Is Present in Placental VSMCs
In this study, we first determined whether the vitamin D metabolic system was present in placental VSMCs. We examined CYP2R1, CYP27B1, VDR, and CYP24A1 expression in cells treated with 1,25(OH) 2 D 3 . We found that CYP2R1 and CYP27B1 were strongly expressed and that CYP24A1 was weakly expressed in untreated control cells. Furthermore, we noticed that expression of CYP27B1 and CYP24A1 were inversely related when cells were treated with 1,25(OH) 2 [20] and in endothelial cells [15] . In the present study, we did not examine biosynthesis of vitamin D in placental VSMCs. However, the presence of CYP2R1, CYP27B1, and CYP24A1 in PVSMC, together with our finding of inducible VDR expression by1,25(OH) 2 D 3 , suggests that a vitamin D biosynthesis and feedback autoregulatory system is present in placental VSMCs. 
BENEFICIAL ROLE OF VITAMIN D IN PLACENTAL VSMCs
Vitamin D Reduces Placental VSMC Contractility
Both human and animal studies have shown that vitamin D levels are inversely associated with blood pressure/hypertension. A cohort study conducted by Griffin et al. [21] showed that vitamin D insufficiency was associated with increased risk of systolic hypertension in women later in life. An animal study by Li et al. [22] found a mechanism of vitamin D as a negative regulator for renin-angiotensin system. Their study revealed that, in wild-type mice, inhibition of 1,25(OH) 2 D 3 synthesis led to an increase in renin expression, whereas 1,25(OH) 2 D 3 administration led to renin suppression. In a cell culture system, these investigators also noticed a marked suppression of renin transcription by 1,25(OH) 2 D 3 through a VDRmediated mechanism [22] . Wong et al. [23] also reported that vitamin D could modulated the vascular tone by reducing endothelium-derived contracting factor production. These findings suggest that suppression of renin-angiotensin system or reduction of endothelium-derived contracting factor production could be part of the cellular response to modulate vascular tone by vitamin D.
Pre-eclampsia is a placental disorder with increased vascular reactivity and reduced uterine blood perfusion. Altered reninangiotensin system and presence of AT-1 autoantibody have been considered to contribute to increased placental vascular resistance in pre-eclampsia [24] [25] [26] . To investigate whether vitamin D may exert beneficial effects on placental vasculature, we specifically tested effects of 1,25(OH) 2 D 3 on placental VSMC contractility by using collagen gel contraction assay as the testing model. The collagen gel contraction assay has been widely used to study contractile function in multiple cell types, including vascular smooth muscle cells [17, 18, 27, 28] . Although this model does not completely mimic isolated intact vessel contraction, it allows us to study contractile activity of a homogenous population of placental VSMC in response to angiotensin II, losartan, and/or 1,25(OH) 2 D 3 separately or in combination. Moreover, this model offers an excellent condition with which to study VSMC function without the influence of external mechanical load such as sheer stress and/ or effects of endothelial-or matrix-derived mediators on smooth muscle cells, as those occur in the intact vessel. Interestingly, using AT-1 receptor blocker losartan as the comparator, we found that, similar to losartan, 1,25(OH) 2 D 3 could diminish angiotensin II-induced placental VSMC contractility, and most significantly, the inhibitory effect of losartan on angiotensin II-induced placental VSMC contraction could be potentiated when 1,25(OH) 2 D 3 was present in culture. According to Poiseuille's law, the increase in flow is proportional to the fourth power of the diameter of a vessel, hence a relative change in vessel diameter will cause an extreme change in blood flow. Therefore, in an in vivo situation, sufficient vitamin D and/or proper vitamin D metabolism in placental vasculature may exert beneficial effects by reducing placental vascular tone and resistance and subsequently result in an increase in placental blood compliance and perfusion. These findings may also have an impact on systemic vasculature, which may provide an explanation of inverted relationship of vitamin D deficiency and hypertension found in epidemiologic studies [1, 29] .
Potential Mechanism of Vitamin D Induced Placental VSMC Relaxation
Vascular resistance depends on the balance between contraction and relaxation of VSMC to establish vascular tone. Smooth muscle contraction results from interaction of myosin and actin filament, essential to this interaction is the phosphorylation of MLC. MYPT1 is the main regulatory subunit of MLCP, which will dephosphorylate MLC and result in relaxation. An animal study conducted by Qiao et al. [30] revealed that deletion of MYPT1 in VSMCs enhanced myosin phosphorylation, thereby induced VSMC contractility and increased blood pressure in study animals, which indicates the important role of MYPT1 in maintaining VSMC relaxation. The activity of MYPT1 is found largely regulated by its own phosphorylation; threonine (Thr-696 and Thr-853) phosphorylation can inhibit its activity whereas serine (Ser-507 and Ser-668) phosphorylation can promote its effect in MLCP. ROCK1 activation by RhoA promotes phosphorylation of regulatory MLC and increase in cell contractility [31, 32] . It has been demonstrated that activation of AT-1 by angiotensin II could increase free intracellular Ca 2þ concentration, which upregulates ROCK1 expression and leads to the phosphorylation of MYPT1 at Thr-696 or Thr-853 and subsequently smooth muscle contraction [30, [33] [34] [35] . Recently, studies found that vitamin D or vitamin D receptor agonist could inhibit RhoA/ ROCK-MYPT1 pathway [36] . To determine whether 1,25(OH) 2 In conclusion, we have made several important findings in this study. First, we found that vitamin D biosynthesis components are present in placental VSMCs. The observations of inverse expression of CYP27B1 and CYP24A1 together with inducible VDR expression by 1,25(OH) 2 D 3 provide evidence of a feedback autoregulatory system of vitamin D existing in placental VSMCs. Second, using angiotensin II as a vasoconstrictive stimulator and AT-1 blocker losartan as a contrast, we found that 1,25(OH) 2 D 3 could not only reduce contractility of placental VSMCs stimulated by angiotensin II, but also potentiate the inhibitory effect mediated by losartan on angiotensin II-induced placental VSMC contraction. Third, we found for the first time that 1,25(OH) 2 D 3 exerts an effect similar to that of losartan on RhoA/ROCK1-MYPT1, that is, to inhibit angiotensin II-induced ROCK1 expression and to induce MYPT1 phosphorylation at Ser-507. ROCK1 can promote contractile force generation by inhibiting MLCP activity. Contrarily, MYPT1 serine phosphorylation could activate MLCP, and MLCP activation is an important regulatory mechanism of smooth muscle cell relaxation. Therefore, ROCK1 inhibition and MYPT1 phosphorylation at Ser-507 may be a plausible mechanism of vitamin D and losartan induced VSMC relaxation that counteracts angiotensin II/AT-1 induced increased VSMC contraction. Whether vitamin D exerts similar effects on the systemic vasculature/ VSMCs warrant further investigation.
